97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02825914 (ClinicalTrials.gov) | September 1, 2016 | 30/6/2016 | CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) | CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) | Colitis, Ulcerative;Inflammatory Bowel Diseases | Dietary Supplement: Casein glycomacropeptide (CGMP);Dietary Supplement: Placebo | University of Aarhus | NULL | Completed | 18 Years | N/A | All | 80 | N/A | Denmark |
| 2 | NCT01534312 (ClinicalTrials.gov) | January 2012 | 13/2/2012 | Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) | Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) | Colitis, Ulcerative;Inflammatory Bowel Diseases | Drug: CGMP protein;Drug: Maximal oral 5ASA | University of Aarhus | Arla Foods | Completed | 18 Years | N/A | Both | 24 | N/A | Denmark |